Ушбу иш иқтибос қилган ишлар

378 та иш

Иш: Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Hallmarks of Cancer: The Next Generation
Douglas Hanahan, Robert A. Weinberg
Шарҳ мақола201118 иқтибос
ABI
Targeting cancer stem cell pathways for cancer therapy
Liqun Yang, Pengfei Shi, Gaichao Zhao +8
Шарҳ мақола20205 иқтибос
ABI
mTOR: a pharmacologic target for autophagy regulation
Young Chul Kim, Kun‐Liang Guan
Шарҳ мақола20154 иқтибос
ABI
Roles of the immune system in cancer: from tumor initiation to metastatic progression
Hugo González, Catharina Hagerling, Zena Werb
Шарҳ мақола20184 иқтибос
ABI
Targeting non-coding RNAs to overcome cancer therapy resistance
Baoqing Chen, Mihnea P. Dragomir, Yang Chen +3
Шарҳ мақола20224 иқтибос
ABI
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Yujie Li, Qin Jiang, Guo-Fan Cao +2
Шарҳ мақола20153 иқтибос
ABI
The Role of mTOR Signaling as a Therapeutic Target in Cancer
N. V. Popova, Manfred Jücker
Шарҳ мақола20213 иқтибос
ABI
Сарлавҳасиз
Бошқа3 иқтибос
ABI
Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells
M.-s. Jung, Jin Kyung Rho, Y-M Kim +7
Мақола20122 иқтибос
ABI
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin, Marco Colombi, Christoph Moroni +1
Шарҳ мақола20112 иқтибос
ABI
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
Anna V. Tinker, Susan Ellard, Stephen Welch +7
Мақола20132 иқтибос
ABI
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
Dos D. Sarbassov, Siraj M. Ali, Do‐Hyung Kim +5
Мақола20042 иқтибос
ABI
mTOR Signaling in Growth Control and Disease
Mathieu Laplante, David M. Sabatini
Шарҳ мақола20122 иқтибос
ABI
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by <i>Nanoparticle Albumin-Bound</i> –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
Diana Cirstea, Teru Hideshima, Scott J. Rodig +15
Мақола20102 иқтибос
ABI
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton, David M. Sabatini
Шарҳ мақола20172 иқтибос
ABI
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer
Pedro C. Barata, Matthew M. Cooney, Prateek Mendiratta +3
Мақола20182 иқтибос
ABI
Autophagy, cancer stem cells and drug resistance
Alexandra G. Smith, Kay F. Macleod
Шарҳ мақола20182 иқтибос
ABI
Overexpression of long noncoding RNA GAS5 suppresses tumorigenesis and development of gastric cancer by sponging miR-106a-5p through the Akt/mToR pathway
Shuaijun Dong, Xiefu Zhang, Dechun Liu
Препринт20192 иқтибос
ABI
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang, Ji Nie, Xuelei Ma +3
Шарҳ мақола20192 иқтибос
ABI
The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary
S Sneha, Rohit P. Nagare, Chirukandath Sidhanth +6
Мақола20202 иқтибос
ABI
The double-edged sword of H19 lncRNA: Insights into cancer therapy
Yun Wei Shermane Lim, Xiaoqiang Xiang, Manoj Garg +4
Шарҳ мақола20202 иқтибос
ABI
Targeting tumor-associated macrophages to synergize tumor immunotherapy
Xiaonan Xiang, Jianguo Wang, Di Lu +1
Шарҳ мақола20212 иқтибос
ABI
Targeting PI3K/Akt signal transduction for cancer therapy
Yan He, Miao Sun, Guo Geng Zhang +4
Шарҳ мақола20212 иқтибос
ABI
mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment
Sahar Mafi, Behzad Mansoori, Shahram Taeb +4
Шарҳ мақола20222 иқтибос
ABI
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
Mengshu You, Zhuolin Xie, Nan Zhang +6
Шарҳ мақола20232 иқтибос
ABI